Global Retinopathy Of Prematurity Therapeutics Market Size By Type (IB-09A0133, Mecasermin Rinfabate), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Retinopathy of Prematurity (ROP) Therapeutics Market was valued at USD 623 million in 2023 and is projected to reach USD 1.18 billion by 2031, expanding at a CAGR of 8.3% during the forecast period from 2023 to 2031. The growth of the ROP therapeutics market is driven by the increasing incidence of premature births globally, growing awareness about neonatal care, and advancements in pharmacologic and surgical interventions. ROP is a potentially blinding eye disorder primarily affecting premature infants, and early detection coupled with effective treatment is critical in preventing vision loss.

Drivers:

1. Rising Incidence of Preterm Births:

The global rise in premature births significantly increases the risk of ROP, particularly among infants born before 31 weeks of gestation. According to the WHO, over 15 million babies are born prematurely each year, fueling the demand for ROP diagnosis and therapeutic solutions.

2. Advancements in Treatment Modalities:

Technological advancements in laser therapy, anti-VEGF (vascular endothelial growth factor) injections, and cryotherapy are enhancing treatment outcomes. Anti-VEGF drugs, such as ranibizumab and bevacizumab, have revolutionized ROP care, offering effective and less invasive options.

3. Government and Nonprofit Initiatives:

Increasing governmental and non-governmental programs aimed at improving neonatal healthcare and early screening have further accelerated the adoption of ROP therapeutics in developing and underdeveloped regions.

Restraints:

1. High Cost of Treatment:

Advanced ROP treatments, including intravitreal injections and laser surgeries, are often expensive and unaffordable in low-income countries. This limits access, particularly in rural and underserved areas.

2. Limited Access to Skilled Professionals:

Effective ROP treatment requires trained ophthalmologists and neonatologists. A shortage of specialized healthcare providers in many regions, particularly in Sub-Saharan Africa and parts of Asia-Pacific, impedes optimal care delivery.

Opportunity:

1. Emerging Markets and Tele-Ophthalmology:

Developing regions such as Latin America, Southeast Asia, and Africa offer lucrative growth potential owing to increasing investments in neonatal care and expanding tele-ophthalmology networks that facilitate remote ROP screening and diagnosis.

2. Drug Development and Pipeline Innovation:

Ongoing research into safer and more effective pharmacologic options, including new anti-VEGF formulations and gene therapy, presents significant opportunities for market growth.

Market by System Type Insights:

Based on treatment type, Anti-VEGF therapy dominated the ROP therapeutics market in 2023. These injections have shown superior efficacy in halting abnormal blood vessel growth compared to traditional treatments. Their minimally invasive nature and strong outcomes position this segment for continued dominance. Meanwhile, Laser therapy remains widely used for advanced cases, particularly in regions where anti-VEGF options are limited or unavailable.

Market by End-use Insights:

In terms of end-use, Neonatal Intensive Care Units (NICUs) accounted for the largest share in 2023. NICUs are critical for early detection and prompt intervention of ROP, especially in tertiary care hospitals. The specialty clinics segment is expected to witness robust growth, supported by expanding outpatient diagnostic capabilities and referral networks.

Market by Regional Insights:

North America held the dominant share of the global ROP therapeutics market in 2023, driven by advanced healthcare infrastructure, widespread screening programs, and high awareness levels. Asia-Pacific is projected to register the highest growth during the forecast period, owing to rising birth rates, increasing access to healthcare, and supportive government policies targeting neonatal care.

Competitive Scenario:

Key players in the Global Retinopathy of Prematurity Therapeutics Market include:

Genentech, Inc. (a member of the Roche Group)

Regeneron Pharmaceuticals, Inc.

Novartis AG

Pfizer Inc.

AbbVie Inc.

Bayer AG

Bausch Health Companies Inc.

Clarity Medical Systems

ThromboGenics NV

These companies are actively focusing on strategic collaborations, regulatory approvals, and innovations in drug delivery systems. For instance:

In 2024, Roche announced the results of a Phase III trial showcasing improved outcomes with a new ranibizumab formulation specifically designed for neonatal use.

In 2023, Regeneron and a leading pediatric research institute launched a joint initiative to study the long-term safety of anti-VEGF therapies in preterm infants.

Scope of Work – Global Retinopathy of Prematurity Therapeutics Market

Report Metric Details

Market Size (2023) USD 623 million

Projected Market Size (2031) USD 1.18 billion

CAGR (2023–2031) 8.3%

Market Segments By Treatment Type (Anti-VEGF, Laser Therapy), By End-use (NICUs, Specialty Clinics)

Growth Drivers Rising Preterm Births, Technological Advancements, Government Initiatives

Opportunities Expansion in Emerging Markets, Pipeline Innovation

Key Market Developments:

2024: Roche published long-term clinical data on ranibizumab's safety in infants, reinforcing its position in the ROP therapeutics market.

2023: Novartis collaborated with a non-profit to expand access to ROP screening tools in sub-Saharan Africa.

2022: ThromboGenics received fast-track designation for its novel pediatric anti-angiogenic drug aimed at early-stage ROP.

FAQs:

1) What is the current market size of the Global Retinopathy of Prematurity Therapeutics Market?

The market was valued at USD 623 million in 2023.

2) What is the major growth driver of the Global Retinopathy of Prematurity Therapeutics Market?

The primary growth driver is the increasing incidence of premature births and advancements in treatment technologies.

3) Which is the largest region during the forecast period in the Global Retinopathy of Prematurity Therapeutics Market?

North America leads the market due to its robust healthcare infrastructure and awareness.

4) Which segment accounted for the largest market share in Global Retinopathy of Prematurity Therapeutics Market?

The Anti-VEGF therapy segment held the largest market share in 2023.

5) Who are the key market players in the Global Retinopathy of Prematurity Therapeutics Market?

Key players include Genentech, Novartis, Regeneron, Pfizer, Bayer, and AbbVie.

Let me know if you'd like this in downloadable document format or if you'd like to generate a chart or infographic from the data.